Literature DB >> 2898902

Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat.

W C Bowman1, I W Rodger, J Houston, R J Marshall, I McIndewar.   

Abstract

The hypothesis that the neuromuscular blocking potency of pancuronium and vecuronium depends on the two acetylcholine moieties present at positions 3 and 17 was tested in cats by examining the neuromuscular profile of several desacetoxy analogues. Blockade of sciatic nerve-induced contraction of the tibialis and soleus muscles, as well as the effects on vagal-induced bradycardia and on sympathetically induced contractions of the nictitating membrane, were studied. The bis-desacetoxy analogue of pancuronium (ORG 7931) was one-fifth as potent as the parent compound as a neuromuscular blocking drug and as a vagolytic agent, but the neuromuscular block was faster in onset and shorter in duration than that produced by pancuronium. The desacetoxy analogues of vecuronium (ORG 8730 and ORG 8764) also were less potent neuromuscular blocking drugs, and, in addition, produced more vagal block than did vecuronium itself. The neuromuscular block produced by these desacetoxy analogues was of more rapid onset and shorter duration than that produced by vecuronium. The results thus showed that the greater neuromuscular blocking potency of pancuronium and vecuronium is lost after removal of one or both of the acetylcholine moieties. An analysis of the relationship between neuromuscular blocking dose and duration of action revealed that it was reciprocal, and it is suggested that a nondepolarizing equivalent of suxamethonium, when discovered, may necessarily be a drug of relatively low potency.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898902

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  29 in total

1.  Estimation of the potency of ORG 9426 using two different modes of nerve stimulation.

Authors:  R A Cooper; R K Mirakhur; P Elliott; G J McCarthy
Journal:  Can J Anaesth       Date:  1992-02       Impact factor: 5.063

Review 2.  Rapacuronium bromide: a review of its use in anaesthetic practice.

Authors:  S V Onrust; R H Foster
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  The role of the amino acid residue at alpha1:189 in the binding of neuromuscular blocking agents to mouse and human muscle nicotinic acetylcholine receptors.

Authors:  P G Purohit; R J Tate; E Pow; D Hill; J G Connolly
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

4.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

5.  An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.

Authors:  J H Proost; J M Wierda; D K Meijer
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

6.  Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation.

Authors:  C Prior; L Tian; A I el Mallah; L Young; J M Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 7.  Pharmacokinetics and pharmacodynamics of rapacuronium bromide.

Authors:  William J Wight; Peter M C Wright
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

9.  Simulation of the kinetics of neuromuscular block: implications for speed of onset.

Authors:  James P Dilger
Journal:  Anesth Analg       Date:  2013-03-01       Impact factor: 5.108

Review 10.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.